ABSTRACT
INTRODUCTION
Pseudomonas aeruginosa (P. aeruginosa) is a versatile nosocomial opportunist, often multiresistant to antibiotics. P. aeruginosa, a non-fermenting Gramnegative rod of great clinical and epidemiological relevance in hospital-acquired infections, is more frequently found in intensive care units and is associated with high morbidity and mortality
.
The increasing rates of antibiotic resistance among P. aeruginosa are of serious concern. P.aeruginosa have significant intrinsic resistance to antibiotics. Antipseudomonal beta-lactams (β-lactams) such as ticarcillin, piperacillin, ceftazidime, cefepime, aztreonam, and the carbapenems have an important therapeutic value
Carbapenem antibiotics are considered the last resort for the treatment of serious infections. These agents have the broadest antibacterial spectrum compared to other β-lactam classes such as penicillins and cephalosporins. Additionally, they are generally resistant to the typical bacterial β-lactamase enzymes which are one of the principal resistance mechanisms of bacteria. They are active against both Gram positive and Gram negative bacteria, with the exception of intracellular bacteria, such as Chlamydiae
Two types of carbapenemases are recognized; serine β-lactamases (having serine at their active site) and the metallo-β-lactamases (MβLs) which contain a metal ion that works as a cofactor for the enzyme's activity
The (MβLs) have emerged as one of the most feared resistance mechanisms because of their ability to hydrolyze virtually all β-lactam agents, including the carbapenems, and because their genes are carried on highly mobile elements. Moreover, MβLs are not susceptible to therapeutic β-lactamase inhibitors 6 .
Over the last decade MβL producing isolates have emerged particularly in P. aeruginosa. These isolates have been responsible for serious infections such as septicemia and pneumonia and have been associated with failure of therapy with carbapenems. In last years, MβL genes have spread from P. aeruginosa to Enterobacteriaceae, and a clinical scenario appears to be developing that could simulate the global spread of extended-spectrum β-lactamases. It is well known that poor outcome occurs when patients with serious infections due to MβL producing organisms are treated with antibiotics to which the organism is completely resistant
Based on amino acid sequence homology, multiple types of MβL genes had been recognized; IMP (imipenemase), VIM (Verona integron-encoded MβL), SPM (Sao Paulo MβL), GIM (German imipenemase), SIM (Seoul imipenemase), NDM-1 (New Delhi MβL), KHM-1 and DIM-1 (Dutch imipenemase)
The problem is aggravated by the fact that most of the MβL-encoding genes reside on integrons and plasmids which in turn allows for the widespread dissemination of these genetic elements 9 . Poor therapeutic outcomes and increased mortality rates have been associated with infections of such organisms. Therefore, early detection of MβL-producing organisms is of crucial importance to permit rapid initiation of strict infection control procedures, allow timely institution of effective therapy and prevent nosocomial spread
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.
METHODOLOGY Patients and samples:
The study was conducted on 100 strains of P.aeruginosa isolated from 220 random clinical samples including: bronchoalveolar lavage (BAL), sputum, wound swab, infected burn wound swab, urine, stool, blood, ear swab and eye swab. The clinical samples were collected from 220 hospitalized inpatients admitted to Benha University hospital and Benha Teaching Hospital, they were 130 males and 90 females and their ages ranged from days to 80 years. This study was approved by Benha University ethical committee and consent was obtained from all patients under study.
Isolation and identification of P. aeruginosa:
Clinical samples were cultured directly on Pseudomonas Cetrimide Agar. Blood samples were inoculated into blood culture bottles (Egyptian Diagnostic Media) then incubated at 37 °C for 7-14 days. Subcultures were done every 48 h on Pseudomonas Cetrimide Agar.The plates were incubated at 37°C for 1-2 days and then the growing organisms were identified as P. aeruginosa by the standard laboratory technique including: Gram staining, colony morphology, motility, pigment production, oxidase reaction, growth at 42 °C, Gelatin liquefaction test and Sugar utilization tests.
Antimicrobial susceptibility testing:
Antimicrobial susceptibility testing was performed on Mueller Hinton agar plates by Kirby-Bauer disc diffusion method and interpreted according to Clinical Laboratory Standards Institute recommendations (CLSI)
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The discs used were: amikacin (30 ug), gentamycin (10 ug) , tobramycin (10 ug), piperacillin+tazobactam (100/10 ug), meropenem (10 ug), imepinem (10 ug), ceftazidime (30 ug), cefoperazone (10 ug), cefotriaxone (30 ug),cefotaxime (30 ug), cefepime (30 ug), aztreonam (30 ug), amoxycillin/clavulanic acid 2:1(30 ug), ciprofloxacin (5 ug), polymixin B (10 ug) and colistin (10 ug) .
Phenotypic detection of MβL activity:
All P. Aeruginosa isolates resistant to imipenem were investigated for MβL production by imipenem + EDTA combined disc test (IMP-EDTA CDT) as described previously by Yong et al 12 .
Briefly, an overnight culture of the test organism was diluted with peptone water to 10 5 CFU/mL and inoculated on plates with Mueller Hinton agar plate using cotton swab. Two imipenem discs (10 μg) were placed at a distance of 4-5 cm from each other on the plate, and appropriate amounts of 10 μl of 0.5 M EDTA solution were added to one of them. The inhibition zones of the imipenem and imipenem-EDTA discs were compared after 16 to 18 hours of incubation aerobically at 35°C. Isolates with enhancement of zone size of more than or equal to 7 mm between imipenem+EDTA disc compared to Imipenem disc alone were considered as MβL positive (Figure 1 ). 
Multiplex PCR for detection of MβL genes:
Multiplex PCR testing of all isolates for MβL genes was done according to Ellington et al 13 to detect each of the five families of acquired MβL genes in a single reaction. Five primer pairs (Biosearch technologies, USA), specific for each family of acquired MβLs listed in (Table 1 ) were used.
DNA extraction:
Total DNAs of the different bacterial isolates were extracted by the DNA extraction kit (Thermo Scientific GeneJET Genomic DNA Purification Kit #K0721) according to manufacturer instructions. The extracted DNA was then stored at -20°C until further processing.
DNA amplification:
Amplification was done using Maxima Hot Start PCR Master Mix #K1051 (Thermo Scientific, EU Lithuania). The PCR mix contained 25ul of PCR master Mix, 1ul of each forward primer, 1ul of each reverse primer, 5ul of the template DNA and the amount completed with nuclease free water to reach a final volume of 50ul. Two PCR reactions were made for each sample. Reaction 1 (M1) was containing three primers (SIM-1, SPM-1, and GIM-1) while reaction 2 (M2) was containing two primers (IMP and VIM).G storm thermal cycler Uk was used for amplification according to the following program: initial denaturation at 95 ºC for 4mins, 45 cycles of denaturation at 95 ºC for 30 s, annealing at 46 ºC for 30 s and extension at 72 ºC for 45 s, followed by final extension at 72 ºC for 10 mins.
DNA detection by agarose gel electrophoresis:
Fifteen μl of each amplified DNA & 100bp ladder (molecular weight marker) were separated on 2% agarose gel containing 0.3 mg/ml of ethidium bromide. The bands were visualized using UV transilluminator (312 nm), photographed & analyzed 14 . Table 1 : Sequence of primers used in amplification of MβL genes 13 .
Primer Primer sequence 5'----------3' Product length

IMP family
570 bp
Statistical analysis:
Data were recorded and analyzed using the computer program SPSS (Statistical package for social science) version 16 to obtain descriptive data in the form of number and percent. Kappa test measure the level of agreement between IMP EDTA CDT and PCR.
RESULTS
The results of this study show that the highest isolation rate of P. aeruginosa was from BAL samples (48%) while no P.aeruginosa strains were isolated from sputum, blood or stool samples ( Table 2) .
Out of 100 strains of P. aeruginosa, 25 isolates (25%) were resistant to imipenem. Nearly 100% of P. aeruginosa strains were resistant to cefotaxim, cefotriaxone, cefoperazone, ceftazidime, cefepime and amoxicillin-clavulanic acid while 100% of them were fully sensitive to colistin and polymyxin B (Table 3) .
PCR was done for all P. aeruginosa isolates and the results revealed that out of 25 imepinem resistant P. aeruginosa isolates, 15(60%) strains were carrying genes for MβL production [13 (52%) strains were carrying VIM gene and 2 strains (8%) were carrying SPM and VIM genes together]. None of Imipenem sensitive strains were carrying MβL genes (Table 4 ) (Figure 2) . IMP-EDTA CDT was done for all 25 Imipenem resistant isolates and the results revealed that 14 out of 25 (56%) P. aeruginosa isolates were positive (MβL producer) (Table 5) .
When comparing the results of IMP-EDTA CDT with the results of PCR, we found that the strength of agreement between them is considered to be very good(Kappa value=0.92)(Table5) and the sensitivity & specificity of the IMP EDTA CDT in relation to PCR was 93.3% and 100% respectively.
Nearly all MβL producers were resistant to most antibiotics used while 100% of them were fully sensitive to colistin and polymyxin B (Table 6 ). 
Fig 2:
Gel electrophoresis of MβL genes in some strains of P. aeruginosa. M is a ladder. Each two adjacent lanes represent two PCR reactions (M2-M1) for one strain of P. aeruginosa. Lanes (1,2) show one band with molecular weight 390 bp (VIM gene) (strain number 2).lanes (3,4) (strain number 1) and (7, 8) (strain number 12) show a band with molecular weight 390 bp (VIM gene) and a band with molecular weight 271 bp (SPM gene). Lanes (5-6) are negative (strain number 20) . Lane (9) shows a band with molecular weight 390 bp (VIM gene) (M2 reaction of strain number 30). Over the last decade, MβL producing isolates have emerged particularly in P.aeruginosa. Poor therapeutic outcomes and increased mortality rates have been associated with infections of such organisms. Therefore, early detection of MβL producing organisms is crucial for optimal treatment of critically ill patients, to permit rapid initiation of strict infection control procedures and to prevent nosocomial spread
.
So, this study was planned for evaluation of IMP-EDTA CDT as a phenotypic screening method for detection of MβL producing P. aeruginosa, detection of MβL genes in those isolates and formulation of antibiotic policy for treatment of infections by MβL producing P.aeruginosa.
In this study a total number of 100 P.aeruginosa isolates were recovered from 220 different specimens (Table 2 ) and the resistance rate of the isolated P.aeruginosa to different antibiotics was (25%) to imipenem and meropenem, (37%) to piperacillin+tazobactam, (93%) to cefotaxim, 99% to cefotriaxone, 89% to cefoperazone, 100% to ceftazidime, (98%) to cefepime, (58%) to aztreonam, (49%) to gentamycin, (47%) to amikacin, (83%) to ciprofloxacin, (99%) to amoxicillin-clavulanic acid and all isolated strains were sensitive to colistin and polymyxin B (Table 3) .
The resistance rate of P. aeruginosa to different classes of cephalosporins in our study was very high. This may be due to the extensive use of them in our hospitals which made P. aeruginosa more resistant to them.
Another study conducted by Gad et al. 18 in Minia, Egypt, the resistance rates of isolated P. aeruginosa from clinical samples were 22% to meropenem, (68%) to cefotaxim, 49% to cefotriaxone, 36% to cefoperazone, (29%) to cefepime, (59%) to gentamycin, (8%) to amikacin, (29%) to ciprofloxacin, (91%) to amoxicillin-clavulanic acid.
Mansour et al. 19 in Zagazig university hospital in Egypt, found that the resistance rates of the isolated P.aeruginosa to different antibiotics were (49.2%) to imipenem and (50.8%) to meropenem, (62.7%) to ceftazidime, (76.3%) to cefepime, (96.6%) to aztreonam, (52.5%) to gentamycin, (54.2%) to amikacin, (64.4%) to ciprofloxacin and (67.8%) to tobramycin.
In a study by Al-Agamy et al. 20 in Saudi Arabia, the resistance rate of the isolated P.aeruginosa to different antibiotics was (38.5%) to imipenem and (38.2%) to meropenem, (50.3%) to piperacillin+tazobactam, (48.2%) to cefotaxim, (48.2)% to cefoperazone, (45%) to ceftazidime, (40.2%) to cefepime, (30.5%) to aztreonam, (40.3%) to gentamycin, (20.2%) to amikacin, (36.8%) to ciprofloxacin. This difference could be attributed to the different rate of use of these antibiotics in different localities.
In the present study, out of 100 P.aeruginosa isolates, 25 isolates (25%) were imipenem resistant and 15 of them (60%) were carrying genes responsible for MβL production (15% of the total number of P.aeruginosa). Thirteen strains (13%) were carrying VIM gene while two strains (2%) were carrying both VIM and SPM-1 genes together. IMP, GIM-1, SIM-1 genes were not detected. None of the imipenem sensitive strains were carrying genes of MβL production ( Table 4) .
Our results coincide with another study in Egypt at Tanta University. Essa and Afifi,
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, performed a study on 40 imipenem resistant and 20 imipenem sensitive strains of P.aeruginosa. They found that (40%) of the imipenem resistant isolates were positive for VIM gene and none of them had IMP gene and none of the imipenem sensitive isolates had any MβLs-gene.
In another study in Egypt, Zafer et al. 22 collected 122 P. aeruginosa isolates from hospitalized patients admitted to Kasr El-Aini Hospital and National Cancer Institute, Cairo University. The resistance rate to imipenem was (39.3%). Out of 122 P. aeruginosa, (27%) were MβL. The isolation rate of VIM-2, NDM-, and IMP-1-like genes were found in 58.3%, 4.2%, and 2.1%, respectively. GIM-, SPM-, SIM-, like genes were not detected in that study.
In Canada, Pitout et al. 17 reported that out of the 241 clinical strains of imipenem-nonsusceptible P. aeruginosa from the Calgary Health Region, 110/241 (46%) were MβL positive using phenotypic methods while 107/241 (45%) were PCR positive for MβL genes: 103/241 (43%) for VIM and 4/241 (2%) for IMP.
In Germany, Valenza et al. 23 , performed a survey in a German university hospital. They found that imipenem resistance was (13.9%) and the proportion of isolates producing MβL was (1.6%) with regard to all P. aeruginosa isolates investigated and (11.7%) with regard to the isolates with imipenem resistance. Molecular analysis revealed VIM-1 and VIM-2 genes.
In Iran, Saderi et al. 24 performed a study to detect isolation rate of MβL producing P.aeruginosa in burn patients. Among 100 strains of P.aeruginosa, 69/100 (69%) strains were imipenem resistant, 65/100 (65% of total strains) were MβL positive by phenotypic methods (94% of imipenem resistant) and 13/69 of imipenem resistant strains (18.8%) carried VIM-2 gene. (VIM-1, IMP-1, 2 were not detected).
Al-Agamy et al. 20 , reported that imipenem resistance in Saudi Arabia is high (38.6%) and MβL is responsible for 20.57% of the resistance. All MβL producing P. aeruginosa were found to harbor VIM-2 gene while none of them carried IMP, GIM-1, SIM-1 or SPM-1 genes.
In a study by Hammami et al. 25 in Tunisia, 16 (67%) MβL-producer strains (out of 24 P. aeruginosa) were positive for VIM-2 gene and one strain (4%) harboured the IMP gene.
In another study by Polotto et al. 26 in Brazil, they reported that (96.4%) of strains were imipenem resistant and the isolates harbouring MβL genes was (30.3%). (17.8%) presented the SPM-1 gene and the IMP-1 was detected in (12.5%).
Arunagiri et al. 16 in India reported that, out of 67 P. aeruginosa isolates, 62.7% (42/67) and 70.1% (47/67) were resistant to imipenem and meropenem respectively and 70.1% (47/67) were found to be MβL producers. Among this 47 MβL producing isolates, 41 (61.1%) strains carried VIM gene and 2 (3%) strains carried IMP gene.
In Algeria, Touati et al.
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, performed a study on 17 imipenem resistant P. aeruginosa strains isolated from surgical intensive care unit at the University Hospital of Annaba. They found VIM-2 gene in 14 out of 17 strains (82.3%).
This controversy in the incidence of strains carrying MβL-genes may be due to variations in the prevalence between different hospitals and geographic areas.
It was suggested that isolates with VIM gene have replaced those with IMP gene that were identified in the 1990s 28 . This agrees with the results of the present work that could not find IMP gene in any of the imipenem resistant isolates.
Since there are no standard guidelines for detection of MβLs, different studies have reported the use of different methods. PCR analysis is the gold standard method for the detection of MβL production, but it is not feasible in routine microbiology laboratory 29 .
In the present study, we used IMP-EDTA CDT for screening for MβL production and comparing its result with the result of PCR and we found that the strength of agreement between them is very good (Kappa value=0.92) (Table 5 ) and the sensitivity & specificity of the IMP-EDTA CDT in relation to PCR was 93.3% and 100% respectively.
The results of our study are in agreement with the studies done by Pandya et al. 29 and Arunagiri et al. 16 who found that the sensitivity of IMP-EDTA CDT was (96.3%) & (94%) respectively, when using PCR as a gold standard. In contrast, Picao et al. 30 reported lower sensitivity of IMP-EDTA CDT (80%) when compared with other methods of detection.
The resistance rates of the tested antimicrobial agents were higher for MβL-producing than non-MβL-producing P. aeruginosa isolates. In this study, the resistance rates in MβL-producing P. aeruginosawere (100%) to imipenem, meropenem, cefotaxim, cefotriaxone, cefoperazone, ceftazidime, cefepime, ciprofloxacin and amoxicillin clavulanic acid, (93%) to gentamycin and tobramycin, (87%) to aztreonam, (80%) to amikacin and (73%) to piperacillin+tazobactam and all isolated strains were sensitive to colistin and polymyxin B (Table 6 ).
Aztreonam is the only β-lactam that may remain fully active against MβL producers 9 . However high proportion (87%) of our strains was resistant to this β-lactam. This could be due to the existence of other mechanisms such as ESβL production, efflux pumps and cephalosporinase hyperproduction 9 . Zavascki et al. 31 in Brazil, agreed with our study. They reported that MβL producing P.aeruginosa were 100% resistant to imipenem, meropenem, ceftazidime and cefepime, 98.8% to ciprofloxacin, 88.4% to piperacillin/tazobactam, and 48.8% to aztreonam and all strains are sensitive to polymyxin B.
Al-Agamy et al. 20 reported that the resistance rate of the isolated MβL producing P.aeruginosa to different antibiotics was (100%) to imipenem, meropenem, cefotaxim, cefoperazone, ceftazidime, cefepime, piperacillin+tazobactam, (63.8%) to ciprofloxacin, (81.9%) to gentamycin, (68%) to amikacin, (16.6%) to polymyxin B and also they detected high resistant rate to aztreonam (63.8%).
In India Ranjan, et al. 32 reported that MβL producing P.aeruginosa were 100% resistant to meropenem, tobramycin and ciprofloxacin , 93% to imipenem, 29% to ceftazidime, 41% to cefepim, 41% to amikacin, 89% to gentamycin and 53% to aztreonam.
CONCLUSIONS
1) MβL producers is a serious problem as they are highly resistant to most antibiotics used while sensitive only to colistin and polymyxin B making treatment options very limited. Therefore, appropriate and regular screening system should be established specially for all imipenem resistant P. aeruginosa isolates for early detection of MβL producers and to prevent wider spread of such strains. 2) VIM gene is the most prevelant one in comparison with other genes of MβL production. 3) IMP-EDTA CDT is a sensitive method for detecting MβL production. It represents a valid alternative to the molecular investigation of MβL genes, making detection possible in routine diagnostic laboratories.
